BGB B167
Alternative Names: BGB-B167Latest Information Update: 15 Jun 2024
Price :
$50 *
At a glance
- Originator BeiGene
- Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD137 antigen antagonists; CEACAM5 protein inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 05 Apr 2024 Adverse events and pharmacodynamics data from preclinical studies in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 09 Dec 2022 BeiGene plans a phase I trial for Solid tumours (Monotherapy, Combination therapy, Metastatic disease, Late-stage disease, Inoperable/Unresectable, Second-line therapy or greater) in March 2023 (NCT05644626)
- 25 Aug 2022 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in Australia (IV) (NCT05494762)